SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
| FROM | TO | |
|---|---|---|
| PERCHERON THERAPEUTICS LIMITED | 04/01/2024 | |
| ANTISENSE THERAPEUTICS LIMITED | 04/01/2024 |
Level 8, 210 George Street, Sydney NSW 2000 GPO Box 3993 Sydney NSW 2001
Tel : 1300 737 760 (in Australia) +61 2 9290 9600 (International)name changed to Percheron Therapeutics Limited | 04/01/2024 |
The suspension of trading in the securities of Antisense Therapeutics Limited will be lifted immediately following the release by ANP of an announcement relating to the request for a trading halt on 15 August 2022. | 19/08/2022 |
The company releases a response to ASX Query. | 19/08/2022 |
The company releases a Long Covid-19 Collaboration Outcomes Presentation. | 19/08/2022 |
World first study utilizing Somalogic SomaScan assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic targets. Provisional patent applications have been filed in the United States (US) to seek protection for these new inventions. A potential therapeutic marker known to be modulated by ATL1102 in DMD patients has been identified as suggestive of its therapeutic potential as a treatment for Long COVID-19. Collaboration with global leader in the clinical research of neurological aspects of Long COVID-19 Dr Koralnik to continue with application for grant funding. Company plans to review its new patent applications with targeted pharmaceutical and diagnostic companies for potential commercial discussions. | 19/08/2022 |
The securities of Antisense Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement relating to the request for a trading halt on 15 August 2022. | 17/08/2022 |
The suspension of trading in the securities of Antisense Therapeutics Limited will be lifted immediately, following the release by ANP of an announcement regarding clinical trial results. | 17/12/2019 |
The data from all nine participants having completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy has affirmed the drug's excellent safety profile and positive drug effects on disease progression endpoints at the low dose tested and in turn the company's plans to advance ATL1102 into a potentially pivotal Phase IIb clinical trial. | 17/12/2019 |
Antisense enters into an agreement with Morgans Corporate Limited to underwrite the balance of the options not yet exercised or committed, to raise $4.1 million. Total funds raised via the options exercise will be $5.5 million. Funds raised from the issue of the Options intended for use towards advancing plans for Phase IIb clinical trial of ATL1102 in DMD and for general working capital and corporate purposes. | 17/12/2019 |
The securities of Antisense Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement regarding clinical trial results. | 16/12/2019 |
we understand that on or about this date the company consolidated its shares 1 for 10 | 13/11/2013 |
The suspension of trading in the securities of Antisense Therapeutics Limited (the "Company") will be lifted immediately, following the release of an announcement by the company regarding a capital raising | 23/03/2012 |
The securities of Antisense Therapeutics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding a capital raising | 23/03/2012 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 17/11/2023 | James Garner | 100,000 | $0.061 | $6,100.00 |
| 26/09/2023 | Gil Price | 400,000 | $0.071 | $28,400.00 |
| 08/05/2023 | James Garner | 300,000 | $0.074 | $22,200.00 |
| 03/10/2022 | Gil Price | 701 | $0.084 | $59.00 |
| 30/09/2022 | Gil Price | 105,208 | $0.086 | $9,048.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Charmaine Gittleson | Non Exec Chairman | 22/03/2021 |
| James Garner | Managing Director, CEO | 08/05/2023 |
| Phillip Hains | CFO, Company Secretary | 09/11/2006 |
| Gil Price | Non Exec Director | 04/10/2021 |
| Alicia Mellors | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
